CytomX gets two grants to support preclinical programs
CytomX CEO Nancy Stagliano said that following closely on the recent Series B financing, they believe these grants are another validation of the potential of their site-directed antibody
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.